ReviewFrontiers in neurology2019
Biomarkers in Inflammatory Myopathies-An Expanded Definition.
Review in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Plasma exchange in adult idiopathic inflammatory myositis: a systematic review and meta-analysis.Clinical rheumatology · 2026Pooled it
- Review
- Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational study.Rheumatology (Oxford, England) · 2025Observational
- Idiopathic inflammatory myopathies related lung disease in adults.The Lancet. Respiratory medicine · 2025Review
- Contribution of major histocompatibility complex class II immunostaining in distinguishing idiopathic inflammatory myopathy subgroups: A histopathological cohort study.Journal of neuropathology and experimental neurology · 2024Article
- Current biomarkers in inclusion body myositis.Journal of neuromuscular diseases · 2024Review
- Clinicopathological features of graft versus host disease-associated myositis.Annals of clinical and translational neurology · 2024Review
- Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases.Acta neuropathologica · 2024Review
- Effectiveness and safety of immunoadsorption as a rescue treatment of inflammatory myopathies: report of three cases and literature review.Therapeutic advances in musculoskeletal disease · 2024Article
- Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies.Journal of neuromuscular diseases · 2024Review
- Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity.Clinical and experimental immunology · 2023Article
- From data to diagnosis: how machine learning is revolutionizing biomarker discovery in idiopathic inflammatory myopathies.Briefings in bioinformatics · 2023Review
- Reader Response: Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis.Neurology · 2023Article
- Transcriptome Profiling of Immune Cell Types in Peripheral Blood Reveals Common and Specific Pathways Involved in the Pathogenesis of Myositis-Specific Antibody-Positive Inflammatory Myopathies.ACR open rheumatology · 2023Article
- Incorporating circulating cytokines into the idiopathic inflammatory myopathy subclassification toolkit.Frontiers in medicine · 2023Article
- High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies.Cells · 2022Article
- Inclusion body myositis and associated diseases: an argument for shared immune pathologies.Acta neuropathologica communications · 2022Review
- Review
- Article
- SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.RMD open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarkers as parameters of pathophysiological conditions can be of outmost relevance for inflammatory myopathies. They are particularly warranted to inform about diagnostic, prognostic, and therapeutic questions. As biomarkers become more and more relevant in daily routine, this review focusses on relevant aspects particularly addressing myopathological features. However, the level of evidence to use them in daily routine at presence is low, still since none of them has been validated in large cohorts of patients and rarely in independent biopsy series. Hence, they should be read as mere expert opinions. The evaluation of biomarkers as well as key biological parameters is an ongoing process, and we start learning about relevance of them, as we must recognize that pathophysiology of myositis is biologically incompletely understood. As such this approach should be considered an essay toward expansion of the definition "biomarker" to myositis, an emerging field of interest in biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.